Andrei Racila
Research Subjects
Andrei Racila has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Maria Stepanova
The Global NASH Council, Washington, DC
2 shared publications - Zobair Younossi
Beatty Liver and Obesity Research Program Inova Health System Falls Church Virginia USA
2 shared publications - Caglayan Keklikkiran
Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye
1 shared publication - Issah Younossi
Center for Outcomes Research in Liver Disease, Washington DC, USA
1 shared publication - Yusuf Yilmaz
Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey
1 shared publication
Latest Publications
- Open Access
- 28 April 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (6) , e00844
Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry
INTRODUCTION: Despite being underappreciated, pruritus and fatigue are not uncommon in metabolic dysfunction-associated steatotic liver disease (MASLD). In this prospective registry-based study, we sought to evaluate the prevalence, predictors, and impact of these symptoms on patient-reported outcomes (PROs) in patients with MASLD from Türkiye, a country with one of the highest burdens of MASLD globally. METHODS: A total of 1,874 Turkish patients from the Global Liver Registry were included. Significant pruritus and fatigue were defined using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis and the Functional Assessment of Chronic Illness Therapy-Fatigue, respectively. PROs were assessed using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Work Productivity and Activity Impairment: Specific Health Problem questionnaire. RESULTS: The prevalence of significant pruritus and fatigue was 37% and 33%, respectively. Both symptoms were significantly associated with female sex, type 2 diabetes, depression, abdominal pain, and lack of regular exercise. Patients with these symptoms had significantly worse PROs, with impairments up to 31% (all P < 0.0001). Over 1–2 years, symptoms persisted in 47%–52% of patients with baseline pruritus and 33%−39% with baseline fatigue. Independent predictors of a higher likelihood of resolution of pruritus included the absence of fatigue at baseline and the lack of abdominal pain, with odds ratios of 0.36 (95% confidence interval: 0.22−0.59) and 0.60 (95% confidence interval: 0.39−0.91), respectively (both P < 0.05). DISCUSSION: Pruritus and fatigue are common in MASLD, significantly impairing PROs and often persisting over time. Regular assessment and management are essential to improve patients' well-being and functioning.
- 28 April 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (6) , e00844
Open AccessPruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry
INTRODUCTION: Despite being underappreciated, pruritus and fatigue are not uncommon in metabolic dysfunction-associated steatotic liver disease (MASLD). In this prospective registry-based study, we sought to evaluate the prevalence, predictors, and impact of these symptoms on patient-reported outcomes (PROs) in patients with MASLD from Türkiye, a country with one of the highest burdens of MASLD globally. METHODS: A total of 1,874 Turkish patients from the Global Liver Registry were included. Significant pruritus and fatigue were defined using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis and the Functional Assessment of Chronic Illness Therapy-Fatigue, respectively. PROs were assessed using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Work Productivity and Activity Impairment: Specific Health Problem questionnaire. RESULTS: The prevalence of significant pruritus and fatigue was 37% and 33%, respectively. Both symptoms were significantly associated with female sex, type 2 diabetes, depression, abdominal pain, and lack of regular exercise. Patients with these symptoms had significantly worse PROs, with impairments up to 31% (all P < 0.0001). Over 1–2 years, symptoms persisted in 47%–52% of patients with baseline pruritus and 33%−39% with baseline fatigue. Independent predictors of a higher likelihood of resolution of pruritus included the absence of fatigue at baseline and the lack of abdominal pain, with odds ratios of 0.36 (95% confidence interval: 0.22−0.59) and 0.60 (95% confidence interval: 0.39−0.91), respectively (both P < 0.05). DISCUSSION: Pruritus and fatigue are common in MASLD, significantly impairing PROs and often persisting over time. Regular assessment and management are essential to improve patients' well-being and functioning.
- Open Access
- 13 May 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (9) , e1
Validation of a Primary Biliary Cholangitis–Specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC
INTRODUCTION: Primary biliary cholangitis (PBC) is a chronic liver disease, leading to cirrhosis and impairment of patient-reported outcomes. We aimed to develop a PBC-specific version of the Chronic Liver Disease Questionnaire (CLDQ) instrument to assess health-related quality of life of patients with PBC. METHODS: From our Liver Database, we included patients with PBC who had CLDQ, clinicolaboratory data, and completed Short Form-36 and The Functional Assessment of Chronic Illness Therapy—Fatigue. The 29 items of CLDQ were subjected to item reduction, exploratory factor analysis, and fed into a standard instrument validation pipeline. RESULTS: Data were available for 108 patients with PBC: 57 ± 11 years, 7% male, 58% cirrhosis, and 24% decompensated cirrhosis (Child B and C). Of 29 CLDQ items, none met the exclusion criteria. Exploratory factor analysis (95% of variance) returned 7 factors. Based on evaluation of factor loadings and face validity, those factors yielded 7 domains (Diet, Emotion, Fatigue, Itch, Symptoms, Sleep, and Worry). Good to excellent internal consistency (Cronbach's α 0.85–0.93) was observed for 5/7 domains. For the remaining 2 domains (Diet and Itch), additional items obtained from patients, experts, and review of the literature were included. For 5 domains, known-group validity tests discriminated between patients with PBC with and without cirrhosis, advanced cirrhosis, and depression (P < 0.05 for 3–5 domains). The CLDQ-PBC domains were correlated with relevant domains of Short Form-36, CLDQ-PBC Fatigue correlated with Fatigue Scale of Functional Assessment of Chronic Illness Therapy—Fatigue (rho = +0.85), and CLDQ-PBC Worry domain negatively correlated with alkaline phosphatase (rho = −0.38, P = 0.0082). DISCUSSION: The CLDQ-PBC has been developed based on the original CLDQ. The new instrument has evidence for internal consistency and validity and is being fully validated using an external cohort.
- 13 May 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (9) , e1
Open AccessValidation of a Primary Biliary Cholangitis–Specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC
INTRODUCTION: Primary biliary cholangitis (PBC) is a chronic liver disease, leading to cirrhosis and impairment of patient-reported outcomes. We aimed to develop a PBC-specific version of the Chronic Liver Disease Questionnaire (CLDQ) instrument to assess health-related quality of life of patients with PBC. METHODS: From our Liver Database, we included patients with PBC who had CLDQ, clinicolaboratory data, and completed Short Form-36 and The Functional Assessment of Chronic Illness Therapy—Fatigue. The 29 items of CLDQ were subjected to item reduction, exploratory factor analysis, and fed into a standard instrument validation pipeline. RESULTS: Data were available for 108 patients with PBC: 57 ± 11 years, 7% male, 58% cirrhosis, and 24% decompensated cirrhosis (Child B and C). Of 29 CLDQ items, none met the exclusion criteria. Exploratory factor analysis (95% of variance) returned 7 factors. Based on evaluation of factor loadings and face validity, those factors yielded 7 domains (Diet, Emotion, Fatigue, Itch, Symptoms, Sleep, and Worry). Good to excellent internal consistency (Cronbach's α 0.85–0.93) was observed for 5/7 domains. For the remaining 2 domains (Diet and Itch), additional items obtained from patients, experts, and review of the literature were included. For 5 domains, known-group validity tests discriminated between patients with PBC with and without cirrhosis, advanced cirrhosis, and depression (P < 0.05 for 3–5 domains). The CLDQ-PBC domains were correlated with relevant domains of Short Form-36, CLDQ-PBC Fatigue correlated with Fatigue Scale of Functional Assessment of Chronic Illness Therapy—Fatigue (rho = +0.85), and CLDQ-PBC Worry domain negatively correlated with alkaline phosphatase (rho = −0.38, P = 0.0082). DISCUSSION: The CLDQ-PBC has been developed based on the original CLDQ. The new instrument has evidence for internal consistency and validity and is being fully validated using an external cohort.